UroAlert - GU Oncology Weekly

April 23, 2026

Videos

Peer-to-Peer Clinical Conversations

Enfortumab Vedotin Plus Pembrolizumab FDA-Approved for Cisplatin-Ineligible MIBC - Matthew Galsky

Matthew Galsky

Elizabeth Plimack speaks with Matthew Galsky about the FDA approval of enfortumab vedotin (PADCEV®) with pembrolizumab (Keytruda®) for cisplatin-ineligible muscle-invasive bladder cancer based on the KEYNOTE-905/EV-303 trial.

Implementing Radioligand Therapy in a Urology Practice: A Discussion of Practical, Regulatory, and Team Considerations - Neal Shore

Neal Shore

Oliver Sartor interviews Neal Shore about implementing radioligand therapy in community urology practice.

Beyond the Abstracts

Neoadjuvant Sacituzumab Govitecan plus Pembrolizumab, Followed by Adjuvant Pembrolizumab, in Patients with Muscle-Invasive Bladder Cancer (SURE-02): A Single-Arm, Phase 2 Study - Beyond the Abstract

Titrating Cabozantinib in Metastatic Renal Cell Carcinoma Patients Using Goldilocks Principle: A Real-World Evidence Study - Beyond the Abstract

Conference Coverage

SES AUA 2026: Topline Results from BOND-003 Cohort P: A Multi-National, Single-Arm Study of Intravesical Cretostimogene Grenadenorepvec for Treatment of High-Risk, Papillary Only, BCG-unresponsive NMIBC 

EAU 2026: Nectin4-Targeted Fluorescence Imaging for Enhanced TURBT: From Preclinical Validation to First in Human Application

EAU 2026: DISTINCT-I: Perioperative Disitamab Vedotin and Tislelizumab Followed by Nephron-Sparing Surgery in High-Risk Upper Tract Urothelial Carcinoma: A Phase 2 Trial

ASCO GU 2026: A Randomized Phase 2 Trial of Nivolumab + Relatlimab + Ipilimumab Versus Nivolumab + Ipilimumab in First Line Advanced RCC

SUO 2025: Neo-SAbR: A Phase II Trial of Neoadjuvant Stereotactic Ablative Radiotherapy for Caval Thrombus in Newly Diagnosed Renal Cell Carcinoma

Articles

Editor Selected Abstracts and Commentaries

Bladder Cancer

Venous thromboembolism in patients with urothelial carcinoma receiving systemic therapy.

Cost-per-responder analysis of TAR-200 versus other Food and Drug Administration-approved novel and generic treatments among patients with Bacillus Calmette-Guérin-unresponsive, high-risk, non-muscle-invasive bladder cancer with carcinoma in situ in the U

A Study to Evaluate Efficacy and Safety of Hydeal Cyst Intravesical Instillations in Non-muscle Invasive Bladder Cancer Patients Treated With Intravesical Chemotherapy or Immunotherapy.

Long-Term Outcomes of Partial Cystectomy for Urothelial Carcinoma In the Era of Bladder Preservation.

Association of patient, disease, and structural characteristics with receipt of intravesical BCG therapy from 2002-2017 and the impact of BCG supply shortages.

Application of the International Bladder Cancer Group prediction model for recurrence-free survival on a national cohort of primary intermediate risk non-muscle invasive bladder cancer.

Oncological Outcomes of Epirubicin-based Hyperthermic Intravesical Chemotherapy in Bacillus Calmette-Guérin (BCG)-naïve Patients and Patients with BCG Failure: A Multicenter Retrospective Observational Study.

Pembrolizumab in Combination with Gemcitabine and Concurrent Hypofractionated Radiation Therapy as Bladder-sparing Treatment for Muscle-invasive Urothelial Cancer of the Bladder: A Multicenter Phase 2 Trial - Beyond the Abstract

The role of Bladder EpiCheck® test in predicting residual tumor after transurethral resection of bladder cancer: Results from a pilot study.

Alternatives to radical cystectomy: a bladder-sparing approach in appropriately selected patients.

U.S. FDA Grants Priority Review to sBLA for PADCEV™ + Keytruda® as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility

Design and Rationale of the ROGUE-1 Registry: A Multicentric Prospective Registry for Primary T1 Nonmuscle-invasive Bladder Cancer.

Guidelines from the cancer (CCAFU) and infection disease (CI-AFU) committees of the French association of Urology for the management of adverse events and complications of BCG.

Germline Variants in Bladder and Upper Tract Urothelial Cancers: Prevalence and Clinical Context in a Large Testing Registry.

Trends in preferred place of death among patients with bladder cancer in the United States, 2000 to 2020.

MTHFD1L in muscle invasive bladder cancer: a multi-cohort study on prognosis and therapeutic response.

Penile & Urethral Cancers

Organ-sparing radiotherapy in penile cancer: therapeutic approaches.

Renal Cancer

Racial/ethnic differences in time to nephrectomy and its association with cancer-specific mortality in localized renal cell carcinoma.

Genetic landscape and functional exploration of kidney cancer predisposition in cross-ancestral populations.

Prognostic and Predictive Value of the Clearseq1-4 Tumor Microenvironment Classification in Localized and Metastatic Clear-Cell Renal Cell Carcinoma.

Automation of four nephrometry scores using 3D models in renal cell carcinoma.

Kidney-specific HIF-1α-dependent ARL10/miR-1271-5p overexpression in clear cell renal cell carcinoma.

Laparoscopic Partial Nephrectomy Versus Microwave Ablation in the Treatment of Renal Masses.

Renal Tumors Harboring FLCN Mutations: Case Series from Clinical Practice.

Percutaneous ablation of T1b renal tumors: a review.

Kura Oncology Reports Darlifarnib plus Cabozantinib Demonstrates Robust Activity in Patients with Clear Cell Renal Cell Carcinoma Previously Treated With Cabozantinib

Clinical and Molecular Validation of the Very Favorable IMDC Risk Group in Metastatic Renal Cell Carcinoma.

The IQGAP1-Claudin4-JNK Signaling Axis as a Differential Biomarker in Renal Cell Carcinoma.

Prostate Cancer

TRPM4 Expression as a Predictive Biomarker and a Mechanistic Driver of Acetalax Activity in Prostate Cancer: Preclinical Efficacy Studies.

Niraparib With Abiraterone Acetate Plus Prednisone as First-Line Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Repair Gene Alterations: Final Analysis of the Asian Subgroup From the MAGNITUDE Study.

Evaluating the Impact of Age on Prostate Cancer Overdiagnosis Using Long-Term Follow-Up From the CAP Randomised Trial.

ProHealth: a co-designed online home-based healthy eating and exercise programme for men with prostate cancer treated with androgen deprivation therapy - a study protocol for a feasibility and preliminary efficacy randomised controlled trial.

Plasma extracellular vesicle proteomics nominates candidate biomarkers of 177Lu-PSMA-617 outcomes in metastatic prostate cancer patients.

B7-H3 Gene Expression Shapes Prognosis and Therapeutic Opportunities Across Prostate Cancer Patient Groups.

Disparities in Access to Severe Incontinence Surgical Treatment with Artificial Urinary Sphincter after Radical Prostatectomy in France: A Nationwide Nested Case-control Study.

The Association of p27 With Prostate Cancer Outcomes: A Secondary Analysis of NRG/RTOG 8610 and 9202.

Finding Holes: Pathologist-Level Performance Using AI for Cribriform Morphology Detection in Prostate Cancer.

Trends and Patterns in Prostate Cancer Diagnostics During the Era of MRI Implementation - Real-world Evidence From a Population-based Study in the Stockholm Region, Sweden 2010-2023.

Nodal maximum standardised uptake value improves PSMA-PET/CT-based nodal staging in intermediate- and high-risk prostate cancer.

The Swedish national guidelines on prostate cancer: recurrent, metastatic and castration resistant disease.

Prostate cancer mortality among men with and without comorbidity: Long-term results from the European randomized study of screening for prostate cancer Rotterdam.

Predicting High-Dose-Rate Brachytherapy Boost Benefit Using Hypoxia and Angiogenesis Gene Expression in Localised Prostate Cancer.

Lessons from the margins: Narratives of black men living beyond prostate cancer.

Clinical validation of a Novel Robotic Device for MR-Guided Prostate Biopsy: Initial Patient Experience.

Protein Kinase D1 Translocates PARP1 to the Membrane and Is Associated With Increased Sensitivity to Cell Viability Inhibition by PARP1 Inhibitor Olaparib.

Redefining standards: a comprehensive systematic review of practice changing advances in GU oncology from ASCO and ESMO 2025.

Health-related Quality of Life With ARPIs in mHSPC: Insights From a Network Meta-analysis.

Phosphorescent Iridium Hydrazinonicotinic Acid (HYNIC) Complexes That Bind to Prostate Specific Membrane Antigen: Potential Photodynamic Therapy of Prostate Cancer.

Racial disparity in microvascular function among non-Hispanic white and non-Hispanic black men with newly diagnosed prostate cancer.

Predicting clinically significant prostate cancer with or without digital rectal exam and MRI data using ClarityDX Prostate models.

Risk-Adapted Follow-up After Negative MRI-Targeted Biopsy in PI-RADS 3-5 Lesions: A Clinical Cohort Study With Diagnostic Stewardship Modeling.

LuRa: Efficacy and Safety of Radium-223 Following [177Lu]Lu-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer.

Convergent evolution of complex structural variants drives therapy resistance in metastatic prostate cancer.

Lymphedema and self-reported swelling among Danish survivors of prostate cancer - prevalence, clinical associations and functional implications.

Predictive value of early PSMA upregulation for the response to enzalutamide ± 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer: substudy of the randomized, phase 2 ENZA-p trial.

Radiotherapy in Men with De Novo Metastatic Prostate Cancer.

Re-Evaluating the Role of Locoregional Therapy in Metastatic Prostate Cancer: A Review of Current Evidence and Evolving Clinical Approaches.

Comparative Performance of Prostate Cancer Risk Prediction Tools in Gay, Bisexual, and Other Men Who Have Sex with Men Versus Heterosexual Men.

Stockholm3 versus Prostate-specific Antigen in Prostate Cancer Screening: 9-year Outcomes Demonstrating Improved Detection of Aggressive Cancers and Reduced Overdiagnosis from the STHLM3 Trial - Beyond the Abstract

The Role of Multimodality Imaging in Selection, Response Assessment, and Follow-up of Patients Receiving 177Lutetium-PSMA-Therapy - Beyond the Abstract

Natural History of Untreated Prostate Cancer: A Comprehensive Review of Long-Term Progression Patterns and Survival Outcomes - Beyond the Abstract

Upper Tract Tumors

Validation of the diagnostic accuracy of a urine-based DNA methylation marker test in patients with upper urinary tract lesions.

Consolidative Surgery for Advanced Upper Urinary Tract Urothelial Carcinoma After Enfortumab Vedotin and/or Immune Checkpoint Inhibitors.

Venous Invasion in Upper Tract Urothelial Carcinoma: Diagnostic Features and Oncologic Outcomes - Beyond the Abstract

Testicular Cancer

Uncovering novel germline variants associated with testicular germ cell tumors by exome sequencing.

Primary extragonadal germ cell tumours: Real-world data from a high-volume centre.

Metabolic profile and skeletal muscle as predictors of survival in testicular germ cell tumors.

Persistent suicide risk in survivors of testicular cancer: A population-based cohort study.

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Add us to your address book View this email as a web page Forward to a colleague Manage your subscriptions Unsubscribe

Copyright ©2026 Digital Science Press, LLC